<DOC>
	<DOCNO>NCT00533702</DOCNO>
	<brief_summary>The primary objective study determine progression-free survival ( PFS ) participants previously untreated metastatic malignant melanoma treat IMC-1121B ( ramucirumab ) alone combination dacarbazine .</brief_summary>
	<brief_title>A Study IMC-1121B ( Ramucirumab ) With Without Dacarbazine Metastatic Malignant Melanoma</brief_title>
	<detailed_description>The purpose study determine antitumor activity safety profile IMC-1121B ( ramucirumab ) use alone combination dacarbazine participant metastatic melanoma receive prior chemotherapy disease .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The participant histologically cytologically confirm melanoma stage IV ( metastatic ) The participant Eastern Cooperative Oncology Performance Status ( ECOG PS ) 01 The participant complete prior radiotherapy , biologic/immunotherapy vaccine therapy ( adjuvant advanced disease ) least six week prior first dose study therapy The participant adequate hematological function [ absolute neutrophil count ( ANC ) ≥ 1500 cells/microliter ( μL ) , hemoglobin ≥ 9 grams/deciliter ( g/dL ) platelets ≥ 100,000 cells/μL ] . The participant adequate hepatic function [ bilirubin within normal limit ( WNL ) , aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) ≤ 2.5 time upper limit normal ( ULN ) , ≤ 5.0 time ULN transaminase elevation due liver metastasis ] The participant serum creatinine ≤ 1.5 x ULN [ calculate creatinine clearance &gt; 60 milliliters/minute ( mL/min ) ] The participant 's urinary protein ≤ 1+ dipstick routine urinalysis [ ( UA ) ; urine dipstick routine analysis ≥ 2+ , 24hour urine protein must demonstrate &lt; 1000 milligram ( mg ) protein 24 hour allow participation study ] The participant must adequate coagulation function define International Normalized Ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 1.5 X ULN Exclusion Criteria The participant mucosal intraocular melanoma The participant know suspected brain leptomeningeal metastases The participant prior cytotoxic chemotherapy metastatic malignant melanoma The participant one line biologic , immunologic vaccinebased therapy metastatic malignant melanoma ( include therapy adjuvant advance disease ) The participant nonhealing wound ulcer The participant know alcohol drug dependency The participant pregnant breastfeed The participant coexist medical psychiatric problem sufficient severity limit compliance study and/or increase risk associate study participation study drug administration interfere interpretation study result The participant ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , psychiatric illness/social situation , serious uncontrolled medical disorder opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Melanoma</keyword>
	<keyword>IMC-1121B</keyword>
	<keyword>ImClone</keyword>
</DOC>